Oil prices are set for a fourth monthly gain as conflict near key shipping routes keeps supply risks front of mind for investors. That kind of backdrop often pushes attention toward Australian businesses that are built for rapid expansion and backed by confident management teams. This article walks through three high growth, high conviction stocks from the local market that fit that description and explains why each deserves a closer look now.
The stocks covered below are just a sample. The full screen surfaced 23 more high growth, high conviction businesses with equally compelling stories that are not included here. To go beyond this shortlist, identify patterns, and analyze the highest conviction ideas for yourself, head straight into the High Growth High Conviction screener .
Emerald Resources (ASX:EMR)
Overview:Emerald Resources is a Perth based gold producer focused on its 100% owned Okvau Gold Project in Cambodia and regional exploration.
Operations:Emerald Resources generated about A$612 million revenue, with roughly A$602 million from Mine Operations and about A$609 million from Cambodia.
Market Cap:A$4.0b
Emerald Resources aligns with the High Growth High Conviction theme through the Okvau mine, which delivered A$612.32 million revenue and A$259.59 million net income in FY2026, supported by reported margins and production guidance. A key consideration for investors is what may occur if a single key assumption about that asset base is stress tested.
If that key assumption is wrong, the DCF valuation analysis for Emerald Resources shows where Emerald Resources' cash flows start to look stretched or surprisingly resilient.
Mesoblast (ASX:MSB)
Overview:Mesoblast develops mesenchymal cell therapies such as Ryoncil and rexlemestrocel-L for severe inflammatory and cardiovascular conditions worldwide.
Operations:Mesoblast generates about US$120 million in revenue from developing and commercializing its allogeneic cellular medicines platform.
Market Cap:A$2.9b
Mesoblast taps directly into the High Growth High Conviction theme because its MPC platform ties future expansion to high-value, scalable therapies.
"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."
What happens to Mesoblast's valuation and funding flexibility depends heavily on how one pivotal late-stage readout reshapes expectations for future demand.
That funding hinge is the real swing factor, and the full narrative for Mesoblast explains how Mesoblast's platform, capital runway and risk profile could be decoupling from headline sentiment.
Pinnacle Investment Management Group (ASX:PNI)
Overview:Pinnacle Investment Management Group runs a multi affiliate funds platform that helps high conviction boutique managers grow by handling distribution, infrastructure and trustee duties.
Operations:Pinnacle Investment Management Group generated about A$110 million from funds management operations, almost all sourced from Australia.
Market Cap:A$3.6b
Pinnacle Investment Management Group matters for a High Growth High Conviction screen because its whole platform is built around scaling specialist fund managers who already back their own ideas with conviction, then plugging them into deeper pools of client capital.
"Expansion of international affiliates and clients, with about one third of A$229.4 billion of affiliate FUM now sourced outside Australia and A$75 billion coming from more than 50 countries, can deepen diversification and support a larger revenue base as offshore fee streams build."
The real test comes if one pressure point quietly shifts the balance between fast growing fee streams and more volatile performance related income.
That tipping point is exactly what the full narrative for Pinnacle Investment Management Group unpacks so you can see where Pinnacle's affiliate engine could be quietly accelerating or stalling beneath the headline numbers.
Seeking Alternatives Before The Crowd
Fresh momentum stories do not stay under the radar for long. Once a breakout is widely caught, ideal entry windows start dropping fast. Scan what others miss and act now.
-
Target reliable income candidates by scanning the 4 dividend fortresses before yields get compressed by investors chasing the same defensive payers.
-
Hunt for overlooked operators in future facing themes with the curated 15 high quality undiscovered gems before their momentum appears on every watchlist.
-
Position ahead of heavy infrastructure spending cycles by reviewing the 41 power grid technology and infrastructure stocks while valuations still reflect limited attention from broader capital.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
